Know Cancer

or
forgot password

The Impact of the Anti-Platelet Agent Aspirin on Angiogenesis Proteins in Women With Breast Cancer


Phase 0
18 Years
95 Years
Open (Enrolling)
Female
Breast Cancer, Angiogenesis

Thank you

Trial Information

The Impact of the Anti-Platelet Agent Aspirin on Angiogenesis Proteins in Women With Breast Cancer


Inclusion Criteria:



- Histologically or cytologically proven breast cancer

- Pre or post-menopausal

- Age >18

- Completed adjuvant non-hormonal therapy >30 days prior to initiation of study
(surgery and/or chemotherapy and/or radiation therapy)

- Platelet count and hemoglobin within normal ranges for local lab within 30 days of
initiation of study therapy

- Receiving tamoxifen therapy for at least 90 days prior to initiation of study
therapy, and is expected to continue that therapy for the duration of the study (75
days)

Exclusion Criteria:

- Chemotherapy, radiation therapy or surgery within 30 days of study therapy

- Current use of aspirin, anti-platelet or anti-coagulation agents on a continuous
basis

- Prior history of gastrointestinal or central nervous system bleeding, or documented
or self-reported blood in stools or bright red blood per rectum

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Changes in pro-angiogenic and anti-angiogenic protein levels.

Outcome Time Frame:

75 days

Safety Issue:

No

Principal Investigator

Chris E Holmes, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Vermont

Authority:

United States: Institutional Review Board

Study ID:

V0801

NCT ID:

NCT00727948

Start Date:

July 2008

Completion Date:

December 2011

Related Keywords:

  • Breast Cancer
  • Angiogenesis
  • Breast cancer
  • Angiogenesis
  • Aspirin
  • Tamoxifen
  • Breast Neoplasms

Name

Location

University Of VermontBurlington,, Vermont  05403